^
Association details:
| Biomarker: | BCR-JAK2 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
Excerpt:
...a xenograft model of NUP214-ABL1 ALL responded to dasatinib up to 8 weeks of treatment (Figure 7D)...Together, these data indicate that EBF1-PDGFRB, BCR-JAK2, NUP214-ABL1 fusions and sequence mutations in IL7R/SH2B3 are transforming, and represent excellent candidates for therapy with currently available TKIs.
DOI:
https://dx.doi.org/10.1016%2Fj.ccr.2012.06.005
Source:
Title:
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Excerpt:
2 ALL xenografts with no identified JAK mutation or CRLF2 rearrangement (xenografts VII and VIII) had markedly decreased leukemia burden with ruxolitinib...Transcriptome sequencing revealed a BCR-JAK2 rearrangement...Taken together, these studies demonstrate the efficacy of ruxolitinib in ALL xenografts with a variety of JAK-activating lesions.
DOI:
https://dx.doi.org/10.1182%2Fblood-2012-03-415448
